Objective-Scavenger receptor BI (SR-BI) is a high-density lipoprotein (HDL) receptor. Recent studies revealed that SR-BI protects against sepsis via modulating innate immunity. However, its role in adaptive immunity is unclear. Methods and Results-SR-BI-null mice exhibited impaired lymphocyte homeostasis as shown by splenomegaly and imbalanced expansion of T and B lymphocytes in the spleens. Importantly, the activated T and B lymphocytes were increased 3-to 4-fold, indicating a heightened active status of T and B lymphocytes. More importantly, in line with the accumulation of the activated T and B lymphocytes, SR-BI-null mice developed systemic autoimmune disorders characterized by the presence of autoantibodies in circulation, the deposition of immune complexes in glomeruli, and the leukocyte infiltration in kidney. Further analyses revealed that SR-BI deficiency enhanced lymphocyte proliferation, caused imbalanced interferon-␥ and interleukin-4 production in lymphocytes, and caused elevated inflammatory cytokine production in macrophages. Furthermore, HDL from SR-BI-null mice exhibited less capability of suppressing lymphocyte proliferation. Scavenger receptor BI (SR-BI, or Scarb1) is a wellestablished high-density lipoprotein (HDL) receptor. 2,3 It mediates intracellular uptake of cholesterol ester from HDL, which plays a key role in regulating plasma HDL cholesterol levels. 4 -7 Mice lacking SR-BI exhibit a 2-fold increase in plasma cholesterol levels and are susceptible to atherosclerosis. 4 -12 Recent reports showed that mutations in human SR-BI cause elevated plasma HDL concentration associated with infertility and changes in cholesterol metabolism in macrophages and platelets, indicating a role of SR-BI in humans. [13] [14] [15] In addition to regulating HDL metabolism, recent studies indicated that SR-BI is a multifunctional protein. It activates endothelial nitric oxide synthase in endothelial cells in the presence of HDL, 16 -19 induces apoptosis in the absence of HDL/endothelial nitric oxide synthase, 20 and negatively regulates cytokine and IgM generation in B lymphocytes. 21 Recent studies revealed that SR-BI protects against endotoxic and septic animal death via multiple mechanisms, including protection against nitric oxide (NO)-induced oxidative damage and suppression of inflammatory cytokine generation in macrophages. [22] [23] [24] In spite of this established role in innate immunity, the function of SR-BI in adaptive immunity remains largely unknown. In this study, we report that mice deficient in SR-BI exhibited impaired lymphocyte homeostasis and developed autoimmunity. Additional studies revealed that SR-BI deficiency enhanced lymphocyte proliferation, caused imbalanced interferon-␥ (IFN-␥) and interleukin-4 (IL-4) production in lymphocytes and elevated inflammatory cytokine production in macrophages, and reduced the inhibitory effect of HDL on lymphocyte proliferation. The current findings extend our understanding about SR-BI and its role in autoimmunity.
L ymphocytes are essential regulators and effectors of the adaptive immune system. Unlike the innate immune cells, activated T and B lymphocytes form long-lived immunologic memory, which provides protective immune responses to a diversity of pathogens. 1 However, improper activation of T and B lymphocytes breaks down the lymphocyte homeostasis that leads to a variety of diseases, such as autoimmune disorders.
Scavenger receptor BI (SR-BI, or Scarb1) is a wellestablished high-density lipoprotein (HDL) receptor. 2, 3 It mediates intracellular uptake of cholesterol ester from HDL, which plays a key role in regulating plasma HDL cholesterol levels. 4 -7 Mice lacking SR-BI exhibit a 2-fold increase in plasma cholesterol levels and are susceptible to atherosclerosis. 4 -12 Recent reports showed that mutations in human SR-BI cause elevated plasma HDL concentration associated with infertility and changes in cholesterol metabolism in macrophages and platelets, indicating a role of SR-BI in humans. [13] [14] [15] In addition to regulating HDL metabolism, recent studies indicated that SR-BI is a multifunctional protein. It activates endothelial nitric oxide synthase in endothelial cells in the presence of HDL, 16 -19 induces apoptosis in the absence of HDL/endothelial nitric oxide synthase, 20 and negatively regulates cytokine and IgM generation in B lymphocytes. 21 Recent studies revealed that SR-BI protects against endotoxic and septic animal death via multiple mechanisms, including protection against nitric oxide (NO)-induced oxidative damage and suppression of inflammatory cytokine generation in macrophages. [22] [23] [24] In spite of this established role in innate immunity, the function of SR-BI in adaptive immunity remains largely unknown. In this study, we report that mice deficient in SR-BI exhibited impaired lymphocyte homeostasis and developed autoimmunity. Additional studies revealed that SR-BI deficiency enhanced lymphocyte proliferation, caused imbalanced interferon-␥ (IFN-␥) and interleukin-4 (IL-4) production in lymphocytes and elevated inflammatory cytokine production in macrophages, and reduced the inhibitory effect of HDL on lymphocyte proliferation. The current findings extend our understanding about SR-BI and its role in autoimmunity.
Materials and Methods

SR-BI-Null Mice
SR-BI
ϩ/Ϫ (B6;129S2-Scarb1 tm1Kri /J) mice were from the Jackson Laboratory. SR-BI Ϫ/Ϫ mice were generated by breeding SR-BI 
Results
Splenomegaly, Imbalanced T and B Lymphocyte Expansion, and Heightened Lymphocyte Activation in Mice Lacking SR-BI
To understand the significance of SR-BI in adaptive immunity, we examined the lymphatic organs from SR-BI-null and wild-type littermates. SR-BI-null mice exhibited splenomegaly (0.173Ϯ0.051 g versus 0.083Ϯ0.031 g for the wild-type) associated with a 2.1-fold increase in total splenocyte number (Figure 1a and 1b) . Histological examination of the enlarged spleens revealed disrupted spleen structure, as shown by increased numbers of small lymphoid nodules that lack a defined marginal zone (Figure 1c ). Immunofluorescent staining showed that these small lymphoid nodules contained densely packed T and B lymphocytes (Supplemental Figure  IIa) . Enlarged lymph nodes were more frequently observed in SR-BI-null mice than in wild-type controls (Supplemental Figure IIb) . There was no significant difference in thymus weight between SR-BI-null and wild-type littermates, but the thymus cellularity in SR-BI-null mice was slightly decreased (Supplemental Figure IIc) .
Fluorescence-activated cell sorting analysis revealed that, compared with wild-type littermates, SR-BI-null mice had a 2-fold increase in the number of B lymphocytes in the spleen (Figure 1e ). Interestingly, compared with the marked increase in the number of B lymphocytes, the T lymphocytes were less expanded (1.4-fold) (Figure 1e) . Actually, the percentages of CD3 ϩ , CD4 ϩ , and CD8 ϩ T lymphocytes were moderately decreased (Figure 1d and 1f) , and there was a 30% reduction in T-to B-cell ratio compared with that of wild-type controls (Figure 1g ), indicating an imbalanced T-and B-cell expansion in mice lacking SR-BI. A 1.8-fold increase in B lymphocytes and a 30% reduction in T-to B-cell ratio were also observed in circulating blood (Supplemental Figure IId) .
We next investigated the effect of SR-BI deficiency on lymphocyte activation. Both T and B cells exhibited an overall hyperreactive feature, as shown by significant increases in the percentages of activated CD3CD69 high T and CD19 CD69 high B cells (Figure 2a) , and 3-to 4-fold increases in the number of activated CD3CD69 high T and CD19 CD69 high B cells (Figure 2b ). We also looked at the effect of SR-BI deficiency on memory T cells using CD44 as marker. Mice lacking SR-BI had significant increases in both the percentage and the number of effector memory (CD4 ϩ CD44 high CD62L low ) CD4 ϩ T lymphocytes (Figure 2c and 2d ). In contrast, there was a significant decrease in the ratio of naïve (CD4 ϩ CD44 low CD62L high ) CD4 ϩ T lymphocytes ( Figure  2c ). The increase in memory T-cell ratio and decrease in naïve T-cell ratio indicate a heightened active status of T lymphocytes and accumulation of the memory T cells.
We also examined activated B lymphocytes using CD138 as a marker. 25 Although there was no significant change in the percentage of plasmablasts (CD138 ϩ ), the number of plasmablasts was increased 2.2-fold in SR-BI-null mice compared with wild-type mice (Figure 2e ).
SR-BI Deficiency Did Not Affect T or B Lymphocyte Development
To understand how SR-BI deficiency leads to disrupted lymphocyte homeostasis, we investigated the effect of SR-BI on lymphocyte development in thymus, bone marrow, and spleen of adult mice. We analyzed the CD4/CD8 profile in the thymus for T lymphocyte development. No difference was observed between SR-BI-null and wild-type littermates (Supplemental Figure IVa) , suggesting that SR-BI deficiency does not affect T lymphocyte development in the thymus. We then examined the development of B lymphocytes. Immature B lymphocytes are first produced in bone marrow; after reaching the IgM ϩ immature stage, these B cells migrate to the spleen, where they continue to develop and differentiate into mature B lymphocytes. As shown in Supplemental Figure IVb and IVc, there was no difference in the percentages of B lymphocyte subsets in bone marrow or spleen between SR-BI-null and wild-type littermates. To determine whether SR-BI deficiency affects T-or B-cell development in early age, we analyzed the T-and B-cell development in 5-to 6-week old mice. No difference was observed between SR-BI-null and wild-type littermates (data not shown).
Taken together, these data suggest that the disordered lymphocyte homeostasis in SR-BI-null mice may not be the consequence of lymphocyte development.
Increased In Vivo Lymphocyte Proliferation in Mice Lacking SR-BI
We then asked whether an increase in lymphocyte proliferation is responsible for the accumulation of lymphocytes in the spleen. We administered bromodeoxyuridine (BrdU) in drinking water and quantified in vivo lymphocyte proliferation by fluorescence-activated cell sorting analysis of the BrdU incorporated cells. Compared with wild-type littermates, SR-BI-null mice displayed a 2-fold increase in proliferating B-cell (B220 ϩ BrdU ϩ ) populations and a slight increase in the percentage of proliferating B cells ( Figure 3a) ; there was a slight increase in the proliferating T-cell (CD3 ϩ BrdU ϩ ) populations and a moderate decrease in the percentage of proliferating CD3 ϩ cells (Figure 3b ). Interestingly, the number of proliferating CD4 ϩ CD44 high BrdU ϩ T cells was significantly increased, but their percentage was slightly decreased in SR-BI-null mice compared with wildtype littermates (Figure 3b and 3c ). This may not be surprising considering the longer life span of the memory T cells, which results in their accumulation.
SR-BI Deficiency Caused Enhanced In Vitro Lymphocyte Proliferation and HDL From SR-BI-Null Mice Lost Inhibitory Effect on Lymphocyte Proliferation in Response to T Cell Receptor/B Cell Receptor Stimuli
To understand the mechanisms of how SR-BI deficiency contributes to the impaired lymphocyte homeostasis, we assessed the effect of SR-BI deficiency on lymphocyte proliferation and cytokine production. We isolated T and B cells from spleen and detected SR-BI expression in T and B cells. Moderate SR-BI expression was detected in T and B cells (Figure 4a and 4b), suggesting that SR-BI may have an intrinsic effect on lymphocyte. Indeed, as shown in Figure 4c and 4d, T and B cells from SR-BI-null mice had 2-fold and 1.5-fold increases in proliferating rate compared with wildtype controls, respectively, indicating enhanced proliferation in basal conditions in the absence of SR-BI.
We next looked at the effect of SR-BI deficiency on lymphocyte proliferation in stimulated conditions. Unexpectedly, T or B cells from SR-BI-null mice did not display a difference in proliferation in response to T cell receptor Early reports showed that HDL has inhibitory effect on Tand B-cell proliferation in stimulated status. 26 -28 SR-BI is an HDL receptor, and mice deficient in SR-BI have abnormal HDL (as shown by larger HDL particles, with a 2-fold increase in cholesterol contents) and changes in associated proteins. 4 -7,29 To test whether this HDL loses its inhibitory effect on lymphocyte proliferation, we stimulated splenocytes with TCR or B cell receptor ligands in the presence or absence of HDL. In agreement with the early reports, HDL from wild-type mice displayed 30% inhibition on CD4 ϩ T-cell proliferation (data not shown). We also looked at the effect of SR-BI on cytokine production in response to TCR stimuli. Interestingly, despite no difference in IFN-␥ production (Figure 4g ), T cells from SR-BI-null mice produced markedly less IL-4 ( Figure 4h ) and displayed a 2-to 3-fold increase in IFN-␥/IL-4 ratio (Figure 4i ) in response to anti-CD3 stimulus. Similar data were obtained when cells were stimulated by both anti-CD3 and anti-CD28, which is a costimulator of CD3 that stimulates T cells. We also examined the effect of SR-BI on cytokine production stimulated by concanavalin A or phorbol 12-myristate 13-acetate/ionomycin, which bypass the TCR to induce T-cell activation, and found no difference suggesting that the SR-BI likely functions via TCR signaling (Figure 4g and 4h). It is worth noting that IFN-␥ belongs to proinflammatory cytokine (Th1 type) and IL-4 belongs to antiinflammatory cytokine (Th2 type). Thus, SR-BI deficiency causes imbalanced Th1/Th2 cytokine production, which may lead to an inflammatory status and contribute to impaired lymphocyte homeostasis.
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Increased Monocyte/Macrophage Populations and Elevated Proinflammatory Cytokine Production in Mice Lacking SR-BI
Recent studies indicated that SR-BI suppresses inflammatory cytokine production by macrophages by regulating Toll-like receptor-4/nuclear factor-B signaling pathway. 24 Macrophage cytokines, such as IL-6, can act as growth factor for lymphocytes. 30 Thus, it is possible that SR-BI deficiency may affect lymphocyte homeostasis, partly through its role in modulating cytokine production in macrophages. To test such a possibility, we quantified CD11c Ϫ CD11b ϩ F4/80 ϩ cells, a major type of monocyte/macrophage in the spleen. 31 As shown in Figure 5a , there was a 1.9-fold increase in the number of CD11c Ϫ CD11b ϩ F4/80 ϩ cells in SR-BI-null mice compared with wild-type littermates. Importantly, in line with the significant increase in monocytes/macrophages, SR-BInull mice had 3-to 4-fold increases in tumor necrosis factor-␣, IL-6, and inducible nitric oxide synthase expression and significant increases in tumor necrosis factor-␣, IL-6, and nitrite/nitrate levels in circulation (Figure 5b to 5d ).
Development of Autoimmunity in Aged SR-BI-Null Mice
Impaired lymphocyte homeostasis with overactivation of T and B lymphocytes, especially the accumulation of long-lived memory CD4
ϩ T cells, is characteristic of systemic autoimmune diseases, such as human systemic lupus erythematosus, and the systemic lupus erythematosus-prone mouse. 32, 33 To assess whether SR-BI deficiency leads to autoimmunity, we quantified circulating autoantibodies in adult and aged mice. The autoantibody levels in adult SR-BI-null mice (Յ30 weeks) were slightly elevated compared with wild-type littermates. For aged SR-BI-null mice (Ͼ30 weeks), there were marked increases in circulating autoantibodies against double-stranded DNA, single-stranded DNA, and histone (Figure 6a ), indicating age-dependent development of autoimmunity in mice lacking SR-BI. Circulating autoantibodies can deposit as immune complexes in kidney glomeruli through entrapment of circulating immune complexes, as well as formation of immune complexes in situ following cross-reaction with components of glomerular basement membranes, which is a common feature of systemic autoimmune disorders. 32, 33 As shown in Figure  6b , using fluorochrome-labeled anti-mouse IgG and C3 antibodies, we detected profound positive staining of IgG and 
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C3 in the glomeruli of SR-BI-null mice (1 of 7 in wild-type versus 7 of 7 in SR-BI-null mice were positive for IgG staining; 2 of 7 in wild-type versus 7 of 7 in SR-BI-null mice were positive for C3 staining). Furthermore, most of the deposition of IgG was colocalized with C3, which suggests the formation of IgG/C3 immune complexes. We also evaluated leukocyte infiltration in the kidney, another common feature of systemic autoimmune disorders. 32, 33 We found that there was a large perivascular accumulation of leukocytes in SR-BI-null mice that was seldom observed in control mice ( Figure 6c ). All of these observations were evidence of age-dependent development of autoimmunity in SR-BIdeficient mice.
Discussion
In this study, we report that SR-BI deficiency leads to impaired lymphocyte homeostasis characterized by splenomegaly and imbalanced expansion of T and B lymphocytes. Importantly, T and B lymphocytes in SR-BI-null mice exhibited a heightened active status as shown by 3-to 4-fold increases in activated T and B lymphocytes. More importantly, in line with the accumulation of the activated T and B Splenocytes were cultured in 10% fetal bovine serum (FBS), and T-and B-cell proliferation was quantified by bromodeoxyuridine (BrdU) incorporation assay. e and f, HDL from SR-BI-null mice had less capability of suppressing lymphocyte proliferation in response to TCR or BCR stimuli by anti-CD3 and lipopolysaccharide (LPS), respectively. Splenocytes were stimulated with anti-CD3 (10 g/mL) or LPS (10 g/mL) in the presence/absence of 40 g/mL HDL isolated from SR-BI-null or wild-type littermates for 96 hours and lymphocyte proliferation was determined by BrdU incorporation assay. g to i, SR-BI deficiency caused imbalanced interferon-␥ (IFN-␥)/interleukin-4 (IL-4) production in response to TCR stimuli. Splenocytes were cultured in 10% FBS in the presence of concanavalin A (ConA) (1 g/mL), phorbol 12-myristate 13-acetate (PMA) (6.5 ng/mL) plus ionomycin (500 ng/mL), anti-CD3 (10 g/mL), or anti-CD3 plus anti-CD28 (10 g/mL) antibodies. After 48 hours, the IFN-␥ and IL-4 levels in the culture supernatant were quantified. In c to i, splenocytes were from 8 to 10-week-old SR-BI Ϫ/Ϫ and SR-BI ϩ/ϩ littermates. Data represent 3 independent experiments. For each experiment, 3 mice per genotype were analyzed. *PϽ0.05 and **PϽ0.01 vs SR-BI ϩ/ϩ mice. Means without a common letter differ, PϽ0.05. mice. b to d, Increased tumor necrosis factor-␣ (TNF-␣), interleukin-6 (IL-6), and inducible nitric oxide synthase (iNOS) expression and production in SR-BI Ϫ/Ϫ mice. Total splenic RNA was isolated from SR-BI Ϫ/Ϫ and SR-BI ϩ/ϩ littermates, and quantitative reverse transcription-polymerase chain reaction was conducted. The data were normalized to 18S rRNA expression. nϭ6 each group. The serum TNF-␣, IL-6, and nitrite/nitrate (NOx) levels were analyzed with the corresponding kits. nϭ16 each group *PϽ0.05 vs SR-BI ϩ/ϩ mice.
lymphocytes, SR-BI-null mice developed systemic autoimmune disorders characterized by the presence of autoantibodies in circulation, the deposition of immune complexes in glomeruli, and the leukocyte infiltration in kidney.
To understand the mechanisms of how SR-BI deficiency contributes to the impaired lymphocyte homeostasis, we assessed the effect of SR-BI on lymphocyte proliferation and cytokine production. We found that SR-BI is moderately expressed in both T and B cells, and its deficiency enhances lymphocyte proliferation in basal status and causes imbalanced IFN-␥/IL-4 production in stimulated status. Furthermore, HDL from SR-BI-null mice exhibited less capability of suppressing lymphocyte proliferation. An early report by Zhu et al demonstrated that SR-BI negatively regulates Toll-like receptor-9 -dependent B-cell activation induced by CpG. 21 Combined with the current finding, these studies suggest that SR-BI has both intrinsic and extrinsic effects on lymphocyte activation and function.
As SR-BI has been shown to suppress inflammatory cytokine production by macrophages via regulating Toll-like receptor-4/nuclear factor-B signaling pathway, 24 and the nuclear factor-B signaling in macrophages plays an important role in lymphocyte activation, 30 we elucidated the effect of SR-BI on macrophage populations and proinflammatory cytokine production. We found a significant increase in the number of splenic monocytes/macrophages; marked increases in tumor necrosis factor-␣, IL-6, and inducible nitric oxide synthase expression; and significant increases in serum tumor necrosis factor-␣, IL-6, and nitrite/nitrate levels in mice lacking SR-BI.
Taken together, these findings suggest that SR-BI regulates lymphocyte homeostasis likely through multiple ways, by modulating the proliferation of lymphocytes, the cytokine production by lymphocytes and macrophages, and the function of HDL.
Glucocorticoid is an immunosuppressive hormone. As an HDL receptor, SR-BI plays an essential role in providing cholesterol for glucocorticoid synthesis in stressed conditions such as endotoxemia, sepsis, and long-term fasting. [23] [24] 34 However, SR-BI deficiency does affect glucocorticoid production in physiological condition, [23] [24] 34 which suggests that the impaired lymphocyte homeostasis may not be caused by a change in glucocorticoid levels.
Recent studies revealed that excess accumulation of cellular cholesterol due to a defect in HDL-mediated cholesterol Figure  Va) . We also assessed the plasma membrane cholesterol level of T and B cells by filipin staining, and no difference was observed between SR-BI-null and wild-type control mice (Supplemental Figure Vb) . Our finding is consistent with a recent report by Ji et al demonstrating that SR-BI expression enhances both cell cholesterol efflux and cholesterol influx from HDL but does not lead to altered cellular cholesterol mass. 39 These data suggest that the impaired lymphocyte homeostasis may not be caused by a change in cellular cholesterol contents. Regulatory T cells and regulatory B cells play important roles in lymphocyte proliferation and activation. To examine whether SR-BI deficiency affects regulatory T cells or regulatory B cells, we quantified regulatory T cells and regulatory B cells using CD4 ϩ CD25 ϩ Foxp3 ϩ and CD19 ϩ CD1 days high CD5 ϩ as markers, respectively. As shown in Supplemental Figure Early studies showed that mice lacking SR-BI exhibit extramedullary erythropoiesis because of defects in erythrocyte maturation. 40, 41 To assess the contribution of the erythrocytes to the observed splenic hypercellularity, we quantified erythrocytes (Ter119 ϩ ) with fluorescence-activated cell sorting in the splenocyte suspension after ACK treatment and found that Ϸ14% of the splenocytes in SR-BI-null mice were Ter119 ϩ cells, whereas only 3% of the splenocytes in wild-type littermates were Ter119 ϩ cells (Supplemental Figure VIIa). Further analysis showed that most of the Ter119 ϩ cells were premature erythrocytes (Supplemental Figure  VIIb) . Thus, the accumulation of erythrocytes accounted for about a 10% increase in splenocyte populations after ACK treatment. We also prepared single-splenocyte suspension without ACK lysis to determine erythrocyte populations. As shown in Supplemental Figure VIIc and VIId, SR-BI-null mice had a 20% increase in Ter119 ϩ cells compared with wild-type littermates (48.2%Ϯ9.6% in SR-BI Ϫ/Ϫ versus 28.5%Ϯ3.2% in SR-BI ϩ/ϩ ), and a great portion of the erythrocytes were premature, as illustrated by a significant increase in the ratio of early (Ter119 high CD71 high , region II)-to-late (Ter119 high CD71 low , region IV) phase erythrocytes in SR-BI-null mice. Thus, accumulation of erythrocytes accounted for about a 20% increase in total splenic cellularity observed in SR-BI-null mice. These data confirmed the presence of extramedullary erythropoiesis in the spleens of SR-BI-null mice, but it only partly contributed to the observed splenic hypercellularity. It is of interest to determine whether and how extramedullary erythropoiesis contributes to the impaired lymphocyte homeostasis in SR-BI-null mice. With the current available evidence, it is difficult to establish a causal relationship between impaired lymphocyte homeostasis and extramedullary erythropoiesis, which warrants further investigation. In summary, SR-BI plays critical roles in modulating lymphocyte activation, proliferation, and cytokine production, and its deficiency leads to impaired lymphocyte homeostasis and autoimmune disorders. Our findings reveal a previously unrecognized role of SR-BI in adaptive immunity.
